| HOME >> BIOLOGY >> TECHNOLOGY |
COLOGNE, Germany, and SINGAPORE, September 20, 2012 /PRNewswire/ --
2.6 million Euro financing will accelerate development of cutting-edge technology for protein analysis
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
The funds raised will be used to drive the further development of AyoxxA's proprietary platform technology and the scale-up of production of its novel bead-based biochips as the company moves towards commercialization.
AyoxxA's technology is aimed at transforming the throughput and accuracy of protein analysis to deliver the analytical power now seen only for DNA arrays. The platform is based around proprietary In-situ Encoded Bead-based Arrays (IEBA) which allow the simultaneous measurement of multiple proteins from minute samples.
Unlike current bead-based microarrays, AyoxxA's IEBA need no physical label to allow multiplex analysis and thus hugely reduce the complexity of downstream analysis while increasing the number of individual proteins that can be analysed at the same time. The arrays are designed to be readily adaptable to standard high throughput screening systems and offer the potential of tens of thousands of ELISA assays in a single well of a biochip.
Dr. Andreas Schmidt, CEO of AyoxxA, said: "This fundraising provides Ayoxxa with the resources to significantly accelerate the scale-up of production of our unique bead-based biochips and, through the expansion of our base in Cologne, prepare to bring our technology to market. We believe our technology can revolutionise protein analysis and with our growing presence in Europe combined with our continued acc
'/>"/>
| SOURCE AyoxxA Copyright©2012 PR Newswire. All rights reserved |
Related biology technology :
1. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
2. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
3. OncoSec Closes $7.75 Million Public Offering
4. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
5. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
6. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
7. Juventas Therapeutics Raises $22.2 Million Series B Financing
8. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
9. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
10. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
11. 23andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service®
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |